ARTICLE | Strategy
Collaborating on combos
How Roche is thinking about cancer immunotherapy combinations
October 26, 2015 7:00 AM UTC
As oncologists and drug developers converge on the idea that combination therapies built on a backbone of PD-L1 or PD-1 inhibitors could lead to cures for some cancers, or keep them at bay for years, every large player has set about collecting components for a winning cocktail.
Roche finds the imperative so strong, and the field so fast-moving, that it has decided to breach the walls between its Pharma Research and Early Development (pRED) and Genentech Research and Early Development (gRED) divisions to pursue immunotherapy combinations...